Matched Related and Unrelated Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 6, 2015, Pages 1037-1045

  Cuellar Rodriguez, Jennifer ^a   Freeman, Alexandra F ^a   Grossman, Jennifer ^b   Su, Helen ^a   Parta, Mark ^c   Murdock, Heardley ^a   Shah, Nirali ^d   Bollard, Catherine ^e   Kong, Heidi H ^d   Moutsopoulos, Niki ^f   Stone, Kelly ^a   Gea Banacloche, Juan ^d   Holland, Steven M ^a   Hickstein, Dennis D ^d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b ALBERTA HEALTH SERVICES   (Canada)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e CHILDREN S RESEARCH INSTITUTE   (United States)

^f NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Allogeneic; DOCK8 deficiency; Transplantation

Indexed keywords

BUSULFAN; FLUDARABINE; METHOTREXATE; TACROLIMUS; DOCK8 PROTEIN, HUMAN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT; VIDARABINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHIMERA; CLINICAL ARTICLE; DEDICATOR OF CYTOKINESIS 8 GENE; ENGRAFTMENT; ERYTHEMA; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVING DONOR; MALE; MARKER GENE; MUCOSA INFLAMMATION; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PHENOTYPE; SCHOOL CHILD; TREATMENT OUTCOME; UNRELATED DONORS; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DEFICIENCY; GENETICS; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOPHENOTYPING; MUTATION; PATHOLOGY; PILOT STUDY; PROCEDURES; SEVERE COMBINED IMMUNODEFICIENCY; SIBLING; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ADULT; BUSULFAN; CHILD; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MUTATION; MYELOABLATIVE AGONISTS; PILOT PROJECTS; SEVERE COMBINED IMMUNODEFICIENCY; SIBLINGS; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; VIDARABINE;

EID: 84937680652     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.01.022     Document Type: Article

References (24)

1. Engelhardt K.R., McGhee S., Winkler S., et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009, 124:1289-1302.
2. Zhang Q., Davis J.C., Lamborn I.T., et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009, 361:2046-2055.
3. Harada Y., Tanaka Y., Terasawa M., et al. DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration during immune responses. Blood 2012, 119:4451-4461.
4. Gatz S.A., Benninghoff U., Schutz C., et al. Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation. Bone Marrow Transplant 2011, 46:552-556.
5. Al-Mousa H., Hawwari A., Alsum Z. In DOCK8 deficiency donor cell engraftment post-genoidentical hematopoietic stem cell transplantation is possible without conditioning. J Allergy Clin Immunol 2013, 131:1244-1245.
6. Metin A., Tavil B., Azik F., et al. Successful bone marrow transplantation for DOCK8 deficient hyper IgE syndrome. Pediatr Transplant 2012, 16:398-399.
7. McDonald D.R., Massaad M.J., Johnston A., et al. Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2010, 126:1304-1305.
8. Bittner T.C., Pannicke U., Renner E.D., et al. Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation. Klin Padiatr 2010, 222:351-355.
9. Barlogis V., Galambrun C., Chambost H., et al. Successful allogeneic hematopoietic stem cell transplantation for DOCK8 deficiency. J Allergy Clin Immunol 2011, 128:420-422.
10. Boztug H., Karitnig-Weiss C., Ausserer B., et al. Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen. Pediatr Hematol Oncol 2012, 29:585-594.
11. Pai S.Y., de Boer H., Massaad M.J., et al. Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency. J Allergy Clin Immunol 2014, 134:221-223.
12. Kletzel M., Jacobsohn D., Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:472-479.
13. Beri R., Chunduri S., Sweiss K., et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010, 45:249-253.
14. Browning B., Thormann K., Donaldson A., et al. Busulfan dosing in children with BMIs >/= 85% undergoing HSCT: a new optimal strategy. Biol Blood Marrow Transplant 2011, 17:1383-1388.
15. Bollard C.M., Gottschalk S., Torrano V., et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014, 32:798-808.
16. Randall K.L., Chan S.S., Ma C.S., et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med 2011, 208:2305-2320.
17. Jabara H.H., McDonald D.R., Janssen E., et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol 2012, 13:612-620.
18. Veys P., Rao K., Amrolia P. Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning. Bone Marrow Transplant 2005, 35(Suppl. 1):S45-S47.
19. Slatter M.A., Rao K., Amrolia P., et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 2011, 117:4367-4375.
20. Mizesko M.C., Banerjee P.P., Monaco-Shawver L., et al. Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2013, 131:840-848.
21. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
22. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
23. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007, 13:56-64.
24. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008, 14:220-228.